FEB 27, 2019 10:30 AM PST

The Current State-of-the-Art Tissue Expression Analysis Platform for Detection & Quantification of Target & Biomarker mRNAs, Splice Variants and Mutations in Preclinical & Clinical Tissues

Presented at: Drug Discovery 2019
Speaker

Abstract

Advanced Cell Diagnostics’ RNAscope products and assay services are utilized widely for tissue-based gene expression analysis in early target validation, preclinical animal efficacy and safety studies and in biomarker development.  RNAscope is clinically validated and performs reliably on routine FFPE archival human tissues and clinical biopsies and any animal model tissues.  Detection limits are at single molecule level, enabling quantitative, cell-specific expression analysis within tissue microenvironments.  There are over 15,000 RNAscope probes in use and over 1,800 publications – more than 2-per-day.  Continuing advances in ACD RNA ISH technology are enable a wide range of applications, including:

-    Multiplexed RNA ISH
-    Dual ISH/IHC for target analysis combined with cell marker staining
-    Isoform-specific assays with exon junction probes
-    Tissue-based gene edit detection
-    Viral RNA and DNA genome detection
-    AAV gene therapy biodistribution analysis
-    CAR-TCR T cell detection and tumor infiltration assays with lentiviral probes

RNAscope technologies are enabling faster and more rigorous tissue-based target and biomarker research with cell-specific, single-molecule sensitive RNA detection in the context of complex disease microenvironments.  The technology, methods and its applications will be illustrated.

Learning Objectives:

1. How RNAscope® in situ hybridization is utilized for tissue-based, cell-specific expression analysis
2. How RNAscope® is enabling gene therapy and cell therapy tissue biodistribution analysis


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
SEP 22, 2022 9:00 AM PDT
SEP 22, 2022 9:00 AM PDT
Date: September 22, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Optimizing platforms for surgical specimen collection and deep human phenotyping was used to enhance protein biomarke...
OCT 11, 2022 8:00 AM PDT
C.E. CREDITS
OCT 11, 2022 8:00 AM PDT
Date: October 11, 2022 Time: 8:00am (PDT), 11:00pm (EDT), 5:00pm (CEST) Multiomic profiling of cell populations at single-cell resolution is revolutionizing scientists’ understanding o...
NOV 01, 2022 10:00 AM PDT
NOV 01, 2022 10:00 AM PDT
Date: November 01, 2022 Time: 10:00am (PDT), 1:00pm (EDT), 6:00pm (CET) Our laboratory developed the Pig-a gene mutation assay as a means to simply and reliably evaluate the potential mutage...
SEP 13, 2022 8:00 AM PDT
SEP 13, 2022 8:00 AM PDT
Date: September 13, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Preparedness against pandemic diseases demands rapid-response vaccine technology and ready-to-use analytical methods...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
FEB 27, 2019 10:30 AM PST

The Current State-of-the-Art Tissue Expression Analysis Platform for Detection & Quantification of Target & Biomarker mRNAs, Splice Variants and Mutations in Preclinical & Clinical Tissues

Presented at: Drug Discovery 2019


Show Resources
Loading Comments...
Show Resources